Clinical research in the field of gynecologic oncology has assumed an improved quality and credibility through the recent efforts of the Gynecologic Oncology Group. Whereas previous efforts at defining prognostic variables for gynecologic neoplasms largely dealt with small groups of patients who were inadequately staged, the validity of careful surgical pathological staging in gynecologic cancer is achieving acceptance as a result of such trials involving large numbers of patients entered on GOG studies. A similar lack of properly designed, properly controlled trials of a combined modality approach to the treatment of gynecologic cancer has been at least partially corrected by recent GOG studies which meet the criteria for proper protocol design and control. Less studied neoplasms such as endometrial carcinoma have received new emphasis within the GOG. Furthermore, a concerted effort at identification of new active chemotherapeutic agents and a logical approach to development of effective combination of these agents in the treatment of gynecologic cancer has been undertaken within the GOG. These current accomplishments of the GOG vindicate a multi-institution, collaborative approach to clinical research in gynecologic oncology to which the University of Mississippi School of Medicine is committed. This institution plans to expand participation within the Gynecologic Oncology Group (GOG) in 4 specific areas: (1) entry of cases onto group-wide protocols, (2) participation in pilot and limited-institutions studies in preparation for group-wide studies, (3) input into the scientific design of studies, and (4) group committee work dealing with protocol development and group administration. Current input is significant in all 4 of these areas as is documented in this application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA013633-16
Application #
3556214
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1989-06-30
Budget Start
1987-05-01
Budget End
1989-06-30
Support Year
16
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Mississippi Medical Center
Department
Type
Schools of Medicine
DUNS #
928824473
City
Jackson
State
MS
Country
United States
Zip Code
39216
Sutton, Gregory; Axelrod, Janice H; Bundy, Brian N et al. (2006) Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 100:349-54
Schilder, Russell J; Blessing, John; Cohn, David E (2005) Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 96:103-7
Tate Thigpen, J; Blessing, John A; DeGeest, Koen et al. (2004) Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 93:336-9
Thigpen, J Tate; Blessing, John A; Olt, George et al. (2003) Cisplatin as second-line therapy in ovarian carcinoma treated initially with single-agent paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 90:581-6
Keys, Henry M; Bundy, Brian N; Stehman, Frederick B et al. (2003) Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. Gynecol Oncol 89:343-53
Spirtos, Nick M; Westby, Cynthia M; Averette, Hervy E et al. (2002) Blood transfusion and the risk of recurrence in squamous cell carcinoma of the cervix: a gynecologic oncology group study. Am J Clin Oncol 25:398-403
Asbury, R; Blessing, J A; Look, K Y et al. (1997) A phase II trial of amonafide in patients with nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol 20:626-7
Malfetano, J H; Blessing, J A; Homesley, H D (1995) A phase II trial of gallium nitrate (NSC #15200) in nonsquamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Am J Clin Oncol 18:495-7
Sutton, G P; Blessing, J A; Barrett, R J et al. (1994) Phase II trial of menogaril in patients with squamous carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 52:229-31
Thigpen, J T; Blessing, J A; Ball, H et al. (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12:1748-53

Showing the most recent 10 out of 23 publications